Table 1.
Study | Year | Ethnicity | Design | Intervention of GLP-1/DPP-4 inhibitor type | Duration of interventions | N (total) | Number of men (%) | Mean age (year) | Mean baseline HbA1c (%) | Mean BMI (kg/m2) | Mean baseline weight (kg) | Mean duration of diabetes (year) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Ahren et al. (15) | 2016 | Caucasians | Double-blindRCT | I: LiraglutideC: Placebo | 26 weeks | 831 | 382 (46) | 43.2 | 8.08 | 28.9 | 83.9 | 21 |
Mathieu et al. (16) | 2016 | Caucasians | Double-blindRCT | I: LiraglutideC: Placebo | 52 weeks | 1389 | 663 (48) | 43.6 | 8.16 | 29.5 | 86.1 | 21.4 |
Dejgaard et al. (17) | 2016 | Caucasians | Double-blindRCT | I: LiraglutideC: Placebo | 24 weeks | 100 | 65 (65) | 48.0 | 8.70 | 30.0 | 93.7 | 22.5 |
Kuhadiya et al. (18) | 2016 | Caucasians | Double-blindRCT | I: LiraglutideC: Placebo | 12 weeks | 63 | 28 (44) | 44.8 | 7.61 | 28.8 | 84.8 | 24 |
Garg et al. (19) | 2013 | Caucasians | Double-blindRCT | I: SaxagliptinC: Placebo | 16 weeks | 125 | 68 (54 | 38.0 | 8.40 | 27.5 | 82 | 21 |
Hari Kumar et al. (26) | 2013 | Asians | Open-label RCT | I: Exenatide/saxagliptinC: No additional drugs | 12 months | 18 | 13 (72) | 27.7 | 9.70 | 21.5 | 57.3 | 0.11 |
Zhao et al. (27) | 2014 | Asians | Open-label RCT | I: SaxagliptinC: No additional drugs | 12 months | 30 | 18 (60) | 47.4 | 6.45 | 23.4 | NA | 1.4 |
Frandsen et al. (28) | 2015 | Caucasians | Double-blindRCT | I: LiraglutideC: Placebo | 12 weeks | 36 | 24 (66) | 37.8 | 8.75 | 23.5 | 75.4 | 18.95 |
Frandsen et al. (29) | 2017 | Caucasians | Double-blindRCT | I: LiraglutideC: Placebo | 12 weeks | 17 | 12 (71) | 36.9 | 8.86 | 24.1 | 77.2 | 20.9 |
BMI, body mass index; HbA1c, glycosylated haemoglobin; NA, not available.